» Articles » PMID: 33912476

Adjunctive S100A8/A9 Immunomodulation Hinders Ciprofloxacin Resistance in in a Murine Biofilm Wound Model

Overview
Date 2021 Apr 29
PMID 33912476
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: is known to contribute to the pathogenesis of chronic wounds by biofilm-establishment with increased tolerance to host response and antibiotics. The neutrophil-factor S100A8/A9 has a promising adjuvant effect when combined with ciprofloxacin, measured by quantitative bacteriology, and increased anti- and lowered pro-inflammatory proteins. We speculated whether a S100A8/A9 supplement could prevent ciprofloxacin resistance in infected wounds.

Method: Full-thickness 2.9cm-necrosis was inflicted on 32 mice. On day 4, in seaweed alginate was injected sub-eschar to mimic a mono-pathogenic biofilm. Mice were randomized to receive ciprofloxacin and S100A8/A9 (n=14), ciprofloxacin (n=12) or saline (n=6). Half of the mice in each group were euthanized day 6 and the remaining day 10 post-infection. Mice were treated until sacrifice. Primary endpoint was the appearance of ciprofloxacin resistant . The study was further evaluated by genetic characterization of resistance, means of quantitative bacteriology, wound-size and cytokine-production.

Results: Three mice receiving ciprofloxacin monotherapy developed resistance after 14 days. None of the mice receiving combination therapy changed resistance pattern. Sequencing of fluoroquinolone-resistance determining regions in the ciprofloxacin resistant isolates identified two high-resistant strains mutated in C248T (MIC>32µg/ml) and a mutation was found in the sample with low level resistance (MIC=3µg/ml). Bacterial densities in wounds were lower in the dual treated group compared to the placebo group on both termination days.

Conclusion: This study supports the ciprofloxacin augmenting effect and indicates a protective effect in terms of hindered ciprofloxacin resistance of adjuvant S100A8/A9 in biofilm infected chronic wounds.

Citing Articles

In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection.

Higazy D, Pham A, van Hasselt C, Hoiby N, Jelsbak L, Moser C ISME J. 2024; 18(1).

PMID: 38478426 PMC: 10980832. DOI: 10.1093/ismejo/wrae036.


Hyperbaric oxygen therapy augments ciprofloxacin effect against biofilm infected chronic wounds in a mouse model.

Laulund A, Schwartz F, Christophersen L, Kolpen M, Jensen P, Calum H Biofilm. 2023; 5:100100.

PMID: 36660364 PMC: 9843175. DOI: 10.1016/j.bioflm.2022.100100.


The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.

Shariati A, Arshadi M, Khosrojerdi M, Abedinzadeh M, Ganjalishahi M, Maleki A Front Public Health. 2023; 10:1025633.

PMID: 36620240 PMC: 9815622. DOI: 10.3389/fpubh.2022.1025633.

References
1.
Jorgensen K, Wassermann T, Jensen P, Hengzuang W, Molin S, Hoiby N . Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013; 57(9):4215-21. PMC: 3754285. DOI: 10.1128/AAC.00493-13. View

2.
Gillitzer R, Goebeler M . Chemokines in cutaneous wound healing. J Leukoc Biol. 2001; 69(4):513-21. View

3.
Martinengo L, Olsson M, Bajpai R, Soljak M, Upton Z, Schmidtchen A . Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies. Ann Epidemiol. 2018; 29:8-15. DOI: 10.1016/j.annepidem.2018.10.005. View

4.
Mori R, Shaw T, Martin P . Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med. 2008; 205(1):43-51. PMC: 2234383. DOI: 10.1084/jem.20071412. View

5.
Malone M, Bjarnsholt T, McBain A, James G, Stoodley P, Leaper D . The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care. 2017; 26(1):20-25. DOI: 10.12968/jowc.2017.26.1.20. View